Hao Jiang

Dr. Hao Jiang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Carbohydrate Polymers
Verified
Journal Article
Closed access
XWXueliang Wang
Xueliang Wang
ZYZimei Yang
Zimei Yang
XXXu Xu
Xu Xu
HJHao Jiang
Hao Jiang
CCChao Cai
Chao Cai
Guangli YuGuangli Yu
Guangli Yu

2 January 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
HJHao Jiang
Hao Jiang
ALAimé López‐Aguilar
Aimé López‐Aguilar
LMLu Meng
Lu Meng
ZGZhongwei Gao
Zhongwei Gao
YLYani Liu
Yani Liu
PWPeng Wu
Peng Wu

22 September 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
XSXindi Shan
Xindi Shan
XWXueliang Wang
Xueliang Wang
HJHao Jiang
Hao Jiang
CCChao Cai
Chao Cai
Jiejie HaoJiejie Hao
Jiejie Hao
Guangli YuGuangli Yu
Guangli Yu
We previously demonstrated that fucoidan with a type II structure inhibited postprandial hyperglycemia by suppressing glucose uptake, but the mechanism remains elusive. Here, we aimed to assess whether the effect of glucose absorption inhibition was related to the basic structure of fucoidans and preliminarily clarified the underlying mechanism. Fucoidans with type II structure and type I structure were prepared from Ascophyllumnodosum (AnF) or Laminariajaponica (LjF) and Kjellmaniellacrassifolia (KcF), respectively. The effects of various fucoidans on suppressing postprandial hyperglycemia were investigated using in vitro (Caco-2 monolayer model), semi-in vivo (everted gut sac model), and in vivo (oral glucose tolerance test, OGTT) assays. The results showed that only AnF with a type II structure, but not LjF or KcF with type I structure, could inhibit the glucose transport in the Caco-2 monolayer and everted gut sac models. A similar result was seen in the OGTT of Kunming mice and leptin receptor-deficient (db/db) mice, where only AnF could effectively inhibit glucose transport into the bloodstream. Furthermore, AnF (400 mg/kg/d) treatment decreased the fasting blood glucose, HbA1c, and fasting insulin levels, while increasing the serum glucagon-like peptide-1 (GLP-1) level in obese leptin receptor-deficient (db/db) mice. Furthermore, surface plasmon resonance (SPR) analysis revealed the specific binding of AnF to Na+/glucose cotransporter 1 (SGLT1), which indicated the effect of AnF on postprandial hyperglycemia could be due to its suppression on SGLT1 activity. Taken together, this study suggests that AnF with a type II structure can be a promising candidate for hyperglycemia treatment.

6 November 2023 in Carbohydrate Polymers
Verified
Journal Article
Closed access
QWQian Wang
Qian Wang
HJHao Jiang
Hao Jiang
HZHongli Zhang
Hongli Zhang
WLWeiqiao Lu
Weiqiao Lu
XWXiao Wang
Xiao Wang
Guangli YuGuangli Yu
Guangli Yu

23 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XWXueliang Wang
Xueliang Wang
ZWZhe Wang
Zhe Wang
DLDi Liu
Di Liu
HJHao Jiang
Hao Jiang
CCChao Cai
Chao Cai
Guangli YuGuangli Yu
Guangli Yu
Type 2 diabetes mellitus (T2DM) is associated with cardiovascular disease (CVD) and sodium glucose cotransporter 2 inhibitors, as oral medications for T2DM treatment have shown the potential to improve vascular dysfunction. The aim of this study was to evaluate the ability of canagliflozin (Cana) to relieve CVD in T2DM mice and its possible action mechanism. Mice with diabetic CVD was conducted by a high-fat diet for 24 weeks, followed by oral gavaging with metformin (200 mg/kg/day) or Cana (50 mg/kg/day) for 6 weeks. The result demonstrated that Cana reduced serum lipid accumulation, and decreased the arteriosclerosis index and atherogenic index of plasma. In addition, Cana treatment reduced the circulating markers of inflammation. More importantly, Cana improved cardiac mitochondrial homeostasis and relieved oxidative stress. Moreover, Cana treatment alleviated the myocardial injury with decreasing levels of serous soluble cluster of differentiation 40 ligand and cardiac troponin I. Thus, cardiovascular abnormality was relieved by suppressing fibrosis and basement membrane thickening, while elevating the cluster of differentiation 31 expression level. Importantly, Cana increased the ratio of gut bacteria Firmicutes/Bacteroidetes and the relative abundance of Alistipes, Olsenella, and Alloprevotella, while it decreased the abundance of Mucispirillum, Helicobacter, and Proteobacteria at various taxonomic levels in mice with diabetic CVD. In short, Cana treatment altered the colonic microbiota composition close to the normal level, which was related with blood lipid, inflammation, and oxidative stress, and might play a vital role in CVD. In general, the improvements in the gut microbiota and myocardial mitochondrial homeostasis may represent the mechanism of Cana on CVD treatment.

4 May 2021 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
XWXueliang Wang
Xueliang Wang
DLDi Liu
Di Liu
ZWZhe Wang
Zhe Wang
CCChao Cai
Chao Cai
HJHao Jiang
Hao Jiang
Guangli YuGuangli Yu
Guangli Yu